Resilience (Blue Ash) Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
1,400
- Latest Deal Type
-
General Corporate Purpose
- Latest Deal Amount
-
$867M
- Investors
-
27
Resilience (Blue Ash) General Information
Description
Operator of a biopharmaceutical manufacturing company intended to change the way medicine is produced. The company offers various customized manufacturing capabilities to serve the requirements of biopharmaceuticals at different stages of the drug development process, from pre-clinical development to commercial supply, ensuring its clients with customized and scalable processes and facilities for complex and novel medicines.
Contact Information
Website
www.resilience.comCorporate Office
- 10901 Kenwood Road
- Blue Ash, OH 45242
- United States
Corporate Office
- 10901 Kenwood Road
- Blue Ash, OH 45242
- United States
Resilience (Blue Ash) Timeline
Resilience (Blue Ash) Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. General Corporate Purpose | 29-Oct-2025 | $867M | Completed | Generating Revenue | ||
| 8. Later Stage VC | 01-Jan-2025 | Completed | Generating Revenue | |||
| 7. Grant | 03-Oct-2024 | Completed | Generating Revenue | |||
| 6. Debt - General | Completed | Generating Revenue | ||||
| 5. Later Stage VC | 10-Jan-2023 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series D) | 06-Jun-2022 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series C) | 01-Aug-2021 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series B) | 23-Oct-2020 | $755M | $805M | Completed | Startup | |
| 1. Early Stage VC (Series A1) | $50M | $50M | Completed | Stealth |
Resilience (Blue Ash) Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | ||||||||
| Series C | ||||||||
| Series B | ||||||||
| Series A2 | 3,991,142 | $0.000100 | 8% | $2.25 | $2.25 | 1x | $2.25 | 2.57% |
| Series A1 | 22,088,402 | $0.000100 | 8% | $2.05 | $2.05 | 1x | $2.05 | 14.23% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Resilience (Blue Ash) Comparisons
Industry
Financing
Details
Resilience (Blue Ash) Competitors (2)
One of Resilience (Blue Ash)’s 2 competitors is Syner-G BioPharma Group, a Private Equity-Backed company based in Framingham, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Syner-G BioPharma Group | Private Equity-Backed | Framingham, MA | ||||
| Pacific BioLabs | Corporation | Hercules, CA |
Resilience (Blue Ash) Patents
Resilience (Blue Ash) Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4782551-A1 | Methods, kits, and systems for identification of vector copy number and integration sites | Pending | 22-Jan-2025 | ||
| US-20260209748-A1 | Methods, kits, and systems for identification of vector copy number and integration sites | Pending | 22-Jan-2025 | ||
| WO-2025184348-A1 | Sterile centrifuge drive systems | Pending | 01-Mar-2024 | ||
| WO-2025171291-A1 | Bacterial strains for protein glycosylation | Pending | 08-Feb-2024 | ||
| US-20260337659-A1 | Detecting contaminants during therapy development and manufacture | Pending | 06-Dec-2023 | C12Q1/6806 |
Resilience (Blue Ash) Signals
Resilience (Blue Ash) Investors (27)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| RIT Capital Partners | Asset Manager | |||
| U.S. Department of Health and Human Services | Government | |||
| Global Health Investment Corporation | Venture Capital | Minority | ||
| Mubadala Investment Company | Sovereign Wealth Fund | Minority | ||
| Omega Funds | Venture Capital | Minority |
Resilience (Blue Ash) Investments & Acquisitions (13)
Resilience (Blue Ash)’s most recent deal was a Merger/Acquisition with Anjarium Biosciences. The deal was made on 03-Dec-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Anjarium Biosciences | 03-Dec-2025 | Merger/Acquisition | Drug Delivery | ||
| Taiwan Bio-Manufacturing | 26-Dec-2023 | Buyout/LBO | Business/Productivity Software | ||
| Joint Venture (Resilience / Lifera) | 28-Aug-2023 | Joint Venture | Construction and Engineering | ||
| AstraZeneca (Manufacturing Base in West Chester, Ohio) | 30-Jan-2023 | Corporate Asset Purchase | Buildings and Property | ||
| Cell Therapy Manufacturing Center | 13-May-2022 | Joint Venture | Biotechnology |
Resilience (Blue Ash) Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Taiwan Bio-Manufacturing | Taipei City, Taiwan | 2023 | |
| Therapure Biopharma | Mississauga, Canada | 1995 |
Resilience (Blue Ash) FAQs
-
When was Resilience (Blue Ash) founded?
Resilience (Blue Ash) was founded in 2020.
-
Where is Resilience (Blue Ash) headquartered?
Resilience (Blue Ash) is headquartered in Blue Ash, OH.
-
What is the size of Resilience (Blue Ash)?
Resilience (Blue Ash) has 1,400 total employees.
-
What industry is Resilience (Blue Ash) in?
Resilience (Blue Ash)’s primary industry is Other Pharmaceuticals and Biotechnology.
-
Is Resilience (Blue Ash) a private or public company?
Resilience (Blue Ash) is a Private company.
-
What is Resilience (Blue Ash)’s current revenue?
The current revenue for Resilience (Blue Ash) is .
-
How much funding has Resilience (Blue Ash) raised over time?
Resilience (Blue Ash) has raised $3.32B.
-
Who are Resilience (Blue Ash)’s investors?
RIT Capital Partners, U.S. Department of Health and Human Services, Global Health Investment Corporation, Mubadala Investment Company, and Omega Funds are 5 of 27 investors who have invested in Resilience (Blue Ash).
-
Who are Resilience (Blue Ash)’s competitors?
Syner-G BioPharma Group and Pacific BioLabs are competitors of Resilience (Blue Ash).
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process